Eli Lilly's $2.8 Billion Psychedelic Bet: High Stakes in a Nascent Market

Related Articles

What's Driving the Bearish Options Activity in Eli Lilly

5 months ago

Why is Eli Lilly Betting on Shingles Vaccines

2 months ago

Why Are Institutional Investors Still Bullish on Eli Lilly

4 months ago

Why is Eli Lilly Betting Big on Orforglipron with a $1.5 Billion Inventory

5 months ago

Category

You may also like

Stock News•3 weeks ago

Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion

Eli Lilly agreed to buy AtaiBeckley Inc. for up to $3.8 billion, highlighting large drugmaker interest in psychedelic medicine.

ATAI

Share

Stock News•3 weeks ago

This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks

Psychedelic pharma stock soared ~50% after a report that Eli Lilly is in takeover talks at a premium, per the report.

LLY

Share

Stock News•1 months ago

Eli Lilly Takes Another Stab at the Market for Painkillers. This Attempt Might Work.

Eli Lilly acquired 4E Therapeutics, a developer of non-addictive painkillers, for an undisclosed amount, aiming to enter the painkiller market.

LLY

Share

Stock News•3 months ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

Johnson & Johnson’s Spravato, a ketamine-derived nasal spray, has reached $1.7B in annual sales. The drug overcame initial hurdles regarding complex delivery methods and heavy regulatory oversight to ...

JNJ

Share